Suppr超能文献

肥胖糖尿病患者的管理

The management of the obese diabetic patient.

作者信息

Albu Jeanine, Raja-Khan Nazia

机构信息

Division of Endocrinology, St. Luke's Roosevelt Hospital, 1111 Amsterdam Avenue, College of Physicians and Surgeons, Columbia University, New York, NY 10025, USA.

出版信息

Prim Care. 2003 Jun;30(2):465-91. doi: 10.1016/s0095-4543(03)00043-5.

Abstract

The prevalence of obesity and diabetes is increasing in the United States and worldwide. These diseases are predicted to explode to epidemic proportions, unless appropriate counteractive measures are taken. Several large studies (DCCT, UKPDS, Kumamoto) clearly showed that intensive glycemic control in the diabetic patient reduced microvascular complications and improved mortality. Despite this, the NHANES III showed that only 50% of diabetics have been able to achieve a HgbAic level that is less than 7%; this suggests the need for a re-evaluation of our approach to these patients. The management of the obese diabetic patient involves glycemic control and weight reduction. These goals are particularly difficult to achieve in the obese diabetic patient because progressive beta-cell dysfunction and increasing insulin resistance necessitates the administration of increasingly higher dosages of insulin, which, in turn, promotes weight gain. A vicious cycle may ensue. Lifestyle modifications with diet and exercise are an essential part of the management of the obese diabetic patient. These measures alone are often insufficient and concomitant pharmacologic therapy is usually required to achieve glycemic and weight control. Oral agents that improve glycemia, decrease insulin resistance, and limit weight gain are desirable. Because of the progressive nature of diabetes, glycemic control with monotherapy often deteriorates over time, which necessitates the addition of other pharmacologic agents, including insulin. When insulin therapy is required in the treatment of the obese diabetic patient, combinations with oral agents that have been shown to minimize the amount of exogenous insulin that is required, may minimize weight gain. In addition, the obese diabetic patient who is poorly controlled with maximum oral hypoglycemic therapy may benefit from weight-reducing agents, such as sibutramine or orlistat. The introduction of these agents at other points in the management of the obese diabetic patients have been successful. Finally, for the severely obese diabetic patient, bariatric surgery may be the only effective treatment. Gastric bypass has been unequivocally shown to produce significant weight loss and improve glycemic control on a long-term basis in the obese diabetic patient. It is recommended that physicians avail themselves of all of these strategies in the management of the obese patient who has type 2 diabetes.

摘要

在美国乃至全球,肥胖症和糖尿病的患病率都在不断上升。预计这些疾病将呈爆发式流行,除非采取适当的应对措施。几项大型研究(糖尿病控制与并发症试验、英国前瞻性糖尿病研究、熊本研究)清楚地表明,糖尿病患者强化血糖控制可减少微血管并发症并降低死亡率。尽管如此,美国国家健康与营养检查调查III显示,只有50%的糖尿病患者能够将糖化血红蛋白水平控制在7%以下;这表明需要重新评估我们对这些患者的治疗方法。肥胖糖尿病患者的管理涉及血糖控制和体重减轻。在肥胖糖尿病患者中实现这些目标尤其困难,因为进行性β细胞功能障碍和胰岛素抵抗增加,需要使用越来越高剂量的胰岛素,而这反过来又会促进体重增加。可能会形成恶性循环。饮食和运动等生活方式的改变是肥胖糖尿病患者管理的重要组成部分。仅靠这些措施往往是不够的,通常需要联合药物治疗来实现血糖和体重控制。理想的口服药物应能改善血糖、降低胰岛素抵抗并限制体重增加。由于糖尿病的进展性,单药治疗的血糖控制往往会随着时间推移而恶化,这就需要添加其他药物,包括胰岛素。当肥胖糖尿病患者需要胰岛素治疗时,与已证明可减少所需外源性胰岛素量的口服药物联合使用,可能会将体重增加降至最低。此外,接受最大剂量口服降糖治疗但控制不佳的肥胖糖尿病患者可能会从减肥药物中获益,如西布曲明或奥利司他。在肥胖糖尿病患者管理的其他阶段引入这些药物已取得成功。最后,对于重度肥胖糖尿病患者,减肥手术可能是唯一有效的治疗方法。胃旁路手术已明确显示可使肥胖糖尿病患者长期显著减重并改善血糖控制。建议医生在管理2型糖尿病肥胖患者时采用所有这些策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验